Feature CytRx awaiting soft tissue sarcoma data in December By Len Zehr What if it were possible to deliver a broad range of potent cancer drugs more optimally, enhancing both their safety and efficacy? That’s the question CytRx (NASDAQ:CYTR) hopes to answer this December when... October 15, 2013